Helix
Enterprise genomics platform for health systems, payers, and life sciences. Health systems run population genomics programs on Helix infrastructure, covering recruitment, clinically actionable disease screening, return of results, and research, built on the proprietary Exome+ assay and a CLIA certified, CAP accredited sequencing lab. The Helix Research Network spans roughly 20 health system members and a reported 400,000+ sequenced participants, feeding GenoSphere, a linked clinico-genomic dataset that passed 500,000 records in June 2026, each combining Exome+ sequencing with an average of 13 years of EHR history and 8 years of claims. AI tooling is a recent layer rather than the foundation: an AI Cohort Builder launched June 2026 and a Model Context Protocol connector for querying the dataset launched July 2026. Health system programs include Cone Health, Sanford Health, WellSpan, St. Luke's University Health Network, HealthPartners, Nebraska Medicine, and Memorial Hermann.
Capability Axes
The core of the product is sequencing chemistry (the Exome+ assay), a CLIA certified lab, and the data linkage that produces GenoSphere. AI tooling is real but recent and additive: a Cohort Builder for research cohort assembly launched June 2026 and an MCP connector for querying the dataset launched July 2026. The company markets AI powered genomic intelligence, but the asset a buyer is acquiring is sequencing capability and a linked dataset, not a model. Included in this index because the AI capability is genuine; graded here because it is a layer rather than the mechanism.
Deployment evidence is strong and specifically named: population genomics programs at Cone Health, Sanford Health, WellSpan, St. Luke's, HealthPartners, Nebraska Medicine, and Memorial Hermann, with a reported 400,000+ participants sequenced across roughly 20 health systems. The company also states that network scale improves variant of uncertain significance resolution, which is a credible mechanism. Held back from A because the headline outcome metric on the vendor's own site, estimated life years saved, is explicitly a modeled projection using a published cost effectiveness framework rather than measured outcomes, and the vendor labels it as such.
No public pricing. Contact the vendor. Two commercial surfaces: enterprise genomics programs contracted with health systems, and separate multi year data access agreements with life sciences organizations. No rate card published for either.
Clearly bounded and consistently described: population genomics programs for health systems, plus data access for payers and life sciences. The company does not claim clinical decision support or diagnostic interpretation beyond genomic screening and return of results.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Enterprise genomics program contracts; separate data access agreements | — | — | Vendor Published |
Two commercial surfaces: enterprise population genomics programs contracted with health systems, and separate multi year data access agreements with life sciences organizations such as those announced with Alnylam and AstraZeneca in 2026. No rate card published for either.